DART: Success Story in High-Grade Neuroendocrine Carcinomas DART: Success Story in High-Grade Neuroendocrine Carcinomas

Patients with high-grade neuroendocrine carcinomas benefit from dual checkpoint inhibition with ipilimumab and nivolumab after single-agent checkpoint inhibition has failed. Is dual checkpoint blockade ready for prime time?Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news